Hannover Rück SE (VIE:HNR1)
Austria · Delayed Price · Currency is EUR | Market Cap | 30.58B -6.8% |
| Revenue (ttm) | 24.30B -0.1% |
| Net Income | 2.87B +27.6% |
| EPS | 23.81 +27.6% |
| Shares Out | n/a |
| PE Ratio | 10.65 |
| Forward PE | 10.98 |
| Dividend | 12.50 (5.00%) |
| Ex-Dividend Date | May 7, 2026 |
| Volume | n/a |
| Open | 250.00 |
| Previous Close | 252.60 |
| Day's Range | 250.00 - 253.60 |
| 52-Week Range | 224.00 - 281.20 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 12, 2026 |
About Hannover Rück SE
Hannover Rück SE, together with its subsidiaries, provides reinsurance products and services in Germany, the United Kingdom, France, Europe, the United States, Asia, Australia, Africa, and internationally. It operates through Property & Casualty Reinsurance; and Life & Health Reinsurance segments. The company provides property and casualty reinsurance solutions for agricultural, livestock, and bloodstock; aviation and space; natural catastrophe; credit, surety, and political risks; cyber; digital; marine and upstream energy; natural catastrophe... [Read more]
Financial Performance
In 2025, Hannover Rück SE's revenue was 25.92 billion, an increase of 12.14% compared to the previous year's 23.11 billion. Earnings were 2.64 billion, an increase of 13.43%.
Financial StatementsNews
Hannover Re price target lowered to EUR 270 from EUR 275 at JPMorgan
JPMorgan lowered the firm’s price target on Hannover Re (HVRRY) to EUR 270 from EUR 275 and keeps a Neutral rating on the shares.
Hannover Re price target lowered to EUR 275 from EUR 290 at JPMorgan
JPMorgan analyst Kamran Hossain lowered the firm’s price target on Hannover Re (HVRRY) to EUR 275 from EUR 290 and keeps a Neutral rating on the shares. Published first on…
Hannover Re price target lowered to EUR 260 from EUR 270 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Hannover Re (HVRRY) to EUR 260 from EUR 270 and keeps an Equal Weight rating on the shares.
Hannover Re price target lowered to EUR 260 from EUR 285 at Citi
Citi analyst James Shuck lowered the firm’s price target on Hannover Re (HVRRY) to EUR 260 from EUR 285 and keeps a Neutral rating on the shares. Published first on…
Hannover Re price target lowered to EUR 270 from EUR 280 at RBC Capital
RBC Capital lowered the firm’s price target on Hannover Re (HVRRY) to EUR 270 from EUR 280 and keeps a Sector Perform rating on the shares.
Hannover Rück SE Earnings Call Transcript: Q1 2026
Q1 2026 saw strong earnings, robust reserve build, and solid investment returns, with P&C and Life & Health segments both performing well. Guidance for 2026 is confirmed despite market softening and geopolitical uncertainty.
Hannover Rück SE Slides: Q1 2026
Hannover Rück SE has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 11, 2026.
Hannover Rück SE Quarterly report: Q1 2026
Hannover Rück SE has published its Q1 2026 quarterly earnings report on May 11, 2026.
Hannover Re price target raised to EUR 280 from EUR 275 at RBC Capital
RBC Capital analyst Mandeep Jagpal raised the firm’s price target on Hannover Re (HVRRY) to EUR 280 from EUR 275 and keeps a Sector Perform rating on the shares. Published…
Hannover Re price target raised to EUR 330 from EUR 312 at Berenberg
Berenberg raised the firm’s price target on Hannover Re (HVRRY) to EUR 330 from EUR 312 and keeps a Buy rating on the shares.
Hannover Rück SE Earnings Call Transcript: Q4 2025
Record net income and a 40% dividend increase highlight robust profitability and strong capital generation in 2025. Prudent reserving, resilient balance sheet, and positive outlook for 2026 underpin confidence in continued growth.
Hannover Rück SE Annual report: Q4 2025
Hannover Rück SE has published its Q4 2025 annual report on March 12, 2026.
Hannover Rück SE Slides: Q4 2025
Hannover Rück SE has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 12, 2026.
Hannover Re added to European Conviction List at Goldman Sachs
Goldman Sachs analysts added Hannover Re (HVRRY) the firm’s European Conviction List as part of its monthly update. The firm sees the company delivering earnings growth despite pricing pressure. Publi...
Hannover Re downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley downgraded Hannover Re (HVRRY) to Equal Weight from Overweight with a price target of EUR 270, down from EUR 300. The firm adjusted ratings in European insurance as…
Hannover Re downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Kamran Hossain downgraded Hannover Re (HVRRY) to Neutral from Overweight with a price target of EUR 290, down from EUR 320. The firm adjusted ratings in the European…
Hannover Rück SE Earnings Call Transcript: Q3 2025
Net income for the first nine months reached EUR 1.96 billion, prompting an increased full-year target of EUR 2.6 billion. Strong P&C and Life & Health performance, prudent reserving, and realized fixed income losses support future growth, with 2026 guidance set at EUR 2.7 billion.
Hannover Rück SE Quarterly report: Q3 2025
Hannover Rück SE has published its Q3 2025 quarterly earnings report on November 10, 2025.
Hannover Rück SE Slides: Q3 2025
Hannover Rück SE has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 10, 2025.
Hannover Rück SE Slides: Company presentation
Hannover Rück SE has posted slides in relation to its latest quarterly earnings report, which was published on November 10, 2025.
Hannover Re price target raised to EUR 290 from EUR 288 at Morgan Stanley
Morgan Stanley analyst Hadley Cohen raised the firm’s price target on Hannover Re (HVRRY) to EUR 290 from EUR 288 and keeps an Overweight rating on the shares. Published first…
Hannover Re downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital downgraded Hannover Re (HVRRY) to Sector Perform from Outperform with a EUR 275 price target The firm has increased confidence that Hannover can maintain current margins for longer…
Hannover Rück SE Transcript: CMD 2025
No major strategy changes were announced, with organic growth, efficiency, and client relationships remaining central. The payout ratio rises to 55%, reserve resiliency is high, and NatCat, life & health, and investments are all positioned for continued growth.
Hannover Rück SE Slides: FY 2025
Hannover Rück SE has posted slides in relation to its FY 2025 quarterly earnings report, which was published on October 9, 2025.
Hannover Re upgraded to Buy from Neutral at UBS
UBS upgraded Hannover Re (HVRRY) to Buy from Neutral with a EUR 280 price target The firm believes the company’s earnings resilience warrants a higher multiple relative to peers. Published…